Skip to content

Comparing liposomal bupivacaine vs ropivacaine wound infiltration in single-port laparoscopy gynecologic surgery on efficacy for postoperative pain: A prospective randomized trial

Comparing liposomal bupivacaine vs ropivacaine wound infiltration in single-port laparoscopy gynecologic surgery on efficacy for postoperative pain: A prospective randomized trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095912
Enrollment
Unknown
Registered
2025-01-15
Start date
2025-02-01
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pain

Interventions

L group: liposomal bupivacaine group:Liposomal bupivacaine wound infiltration
R group: Ropivacaine group:Ropivacaine wound infiltration

Sponsors

Guangzhou Women and Children's Medical Center
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: ASAI-III patients aged 18-60 years with elective gynecologic single-port laparoscopic surgery

Exclusion criteria

Exclusion criteria: 1. The patient does not agree to participate in the clinical study; 2. Local anesthetic allergy; 3. Patients with chronic pain who require the use of preoperative opioid analgesics; 4. Those who are contraindicated to regional infiltration anesthesia. 5. Previous history of dementia, psychosis or other central nervous system diseases; 6. The patient is in poor general condition with a history of serious cardiovascular system, respiratory system, digestive system, urinary system or central nervous system diseases; 7. The patient has had any of the following conditions within 12 months before surgery: myocardial infarction, severe/unstable angina, coronary artery bypass grafting, congestive heart failure, cerebrovascular accident, pulmonary embolism; 8. Pregnant women; 9. Those who cannot cooperate with follow-up or have poor compliance.

Design outcomes

Primary

MeasureTime frame
NRS pain score;

Secondary

MeasureTime frame
QoR-15 Score;Morphine equivalent;Vital sign;Side effect;

Countries

China

Contacts

Public ContactLingyu Wang

Guangzhou Women and Children's Medical Center

12881977@qq.com+86 188 1689 6080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026